A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
2014년 10월 3일 업데이트: Eli Lilly and Company
Pharmacodynamics of LY2963016 Compared to LANTUS® in Subjects With Type 1 Diabetes Mellitus
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes.
Following each dose, participants will undergo a glucose clamp which lasts for 42 hours each time.
There will be at least 7 days between the two periods, during which time there will be no study treatment, but participants will resume their regular therapy.
The duration of this study can be up to 9.5 weeks.
The purposes of this study are to understand how the blood sugar lowering effect of LY2963016 compares to that of Lantus, and to determine how LY2963016 and Lantus are metabolized by participants with type I diabetes.
연구 개요
연구 유형
중재적
등록 (실제)
20
단계
- 1단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
-
Neuss, 독일, 41460
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- have type 1 diabetes mellitus (T1DM) based on the disease diagnostic criteria
- have had a duration of diabetes ≥1 year
- have hemoglobin A1c ≤10.0%
- have fasting C-peptide ≤0.3 nanomoles per liter (nmol/L)
- have a body mass index ≤29 kilograms per square meter (kg/m²)
- have venous access sufficient to allow blood sampling and cannulation for clamp procedures
Exclusion Criteria:
- are currently enrolled in, have completed, or discontinued within the last 30 days from, a clinical trial involving an investigational drug or device or off-label use of a drug or device
- have a total insulin requirement >1.2 units per kilogram per day (U/kg/day)
- have a history of proliferative retinopathy
- have known allergies to insulin glargine, insulin lispro, heparin, or related compounds
- have an electrocardiogram (ECG) reading considered outside the normal limits
- have an abnormal blood pressure
- have abnormal clinical laboratory tests
- have a history or presence of/significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
- history of deep leg vein thrombosis or a frequent appearance of deep leg vein thrombosis in first-degree relatives
- show evidence of significant active neuropsychiatric disease
- regular use of known drugs of abuse and/or show positive findings on drug screening
- show evidence of human immunodeficiency virus (HIV) and/or positive human HIV antibodies
- show evidence of hepatitis C and/or positive hepatitis C antibody
- show evidence of hepatitis B and/or positive hepatitis B surface antigen
- are women with a positive pregnancy test or women who are lactating
- have an average weekly alcohol intake that exceeds 21 units per week (males) or 14 units per week (females)
- had more than 1 episode of severe hypoglycemia within 6 months prior to study
- undergoing therapy for a malignancy other than basal cell or squamous cell skin cancer
- had a blood transfusion or severe blood loss within 3 months; made a blood donation within 30 days prior to study entry; or have known hemoglobinopathy, haemolytic anemia, or sickle cell anemia
- are receiving systemic glucocorticoid therapy
- have irregular sleep/wake cycle (for example, participants who sleep during the day and work during the night)
- show a history of adverse reactions to heparin, including heparin-induced thrombocytopenia
- smoke more than 10 cigarettes (or equivalent other tobacco products) per day
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 더블
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: LY2963016
A single 0.3 units per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously followed by a minimum washout period of 7 days.
|
Single 0.3 U/kg dose administered subcutaneously
|
|
활성 비교기: Lantus
A single 0.3 U/kg dose of Lantus will be administered subcutaneously followed by a minimum washout period of 7 days.
|
Single 0.3 U/kg dose administered subcutaneously
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pharmacodynamics: Duration of Action of LY2963016 and Lantus
기간: Periods 1 and 2: Baseline up to 42 hours postdose
|
Duration of action is defined as the period of time elapsed between dose administration and the time at which the participant's blood glucose is consistently >150 milligrams/deciliter (mg/dL) without any glucose infusion.
Participants whose blood glucose did not rise to 150 mg/dL were censored 42 hours postdose.
|
Periods 1 and 2: Baseline up to 42 hours postdose
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Glucose Infusion Rate (Rmax)
기간: Periods 1 and 2: Baseline up to 42 hours postdose
|
Rmax is the maximum infusion rate of glucose administered intravenously needed to maintain a target blood glucose level of 100 milligrams/deciliter (mg/dL) [5.6 millimoles/Liter (mmol/L)] and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure.
During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate.
Data presented are the maximum infusion rates, adjusted by body weight.
|
Periods 1 and 2: Baseline up to 42 hours postdose
|
|
Total Glucose Infused (Gtot)
기간: Periods 1 and 2: Baseline up to 42 hours postdose
|
Gtot is the total glucose infusion over the clamp duration and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure.
During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate.
Data presented are the total glucose infused, adjusted by body weight.
|
Periods 1 and 2: Baseline up to 42 hours postdose
|
|
Time of Maximum Glucose Infusion Rate (tRmax)
기간: Periods 1 and 2: Baseline up to 42 hours postdose
|
tRmax is the time to reach maximum glucose infusion rate and is used to measure the study drug action over time as measured by the euglycaemic clamp procedure.
During the euglycaemic clamp procedure, blood glucose concentrations are held constant after the administration of study drug by adjusting the exogenous glucose infusion rate.
|
Periods 1 and 2: Baseline up to 42 hours postdose
|
|
Pharmacokinetics: Maximum Concentration (Cmax) of LY2963016 and Lantus
기간: Periods 1 and 2: Baseline up to 42 hours postdose
|
Cmax was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.
|
Periods 1 and 2: Baseline up to 42 hours postdose
|
|
Pharmacokinetics: Area Under the Concentration-time Curve (AUC) of LY2963016 and Lantus
기간: Periods 1 and 2: Baseline up to 42 hours postdose
|
AUC was not analyzed because of insufficient data due to concentrations being below the quantifiable lower limit of the assay.
|
Periods 1 and 2: Baseline up to 42 hours postdose
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2012년 5월 1일
기본 완료 (실제)
2012년 7월 1일
연구 완료 (실제)
2012년 7월 1일
연구 등록 날짜
최초 제출
2012년 5월 15일
QC 기준을 충족하는 최초 제출
2012년 5월 15일
처음 게시됨 (추정)
2012년 5월 17일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2014년 10월 7일
QC 기준을 충족하는 마지막 업데이트 제출
2014년 10월 3일
마지막으로 확인됨
2014년 10월 1일
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
제1형 당뇨병에 대한 임상 시험
-
Rhythm Pharmaceuticals, Inc.완전한Pro-opiomelanocortin(POMC), Proprotein Convertase Subtilisin/Kexin Type 1(PCSK1) 및 Leptin 수용체(LepR) 유전자 돌연변이미국, 이스라엘, 캐나다, 독일, 그리스, 이탈리아, 포르투갈
-
Duke Street Bio Ltd모병Advanced Malignancies With Homologous Recombination Deficiency (HRD) (Breast, Ovarian, mCRPC, Pancreatic Ductal Adenocarcinoma (PDAC), Brain Metastases)스페인, 프랑스, 헝가리, 미국
-
Hangzhou SynRx Therapeutics Biomedical Technology...모병유방암 | 난소 암 | 고급 고형 종양 | 전이성 고형 종양 | BRCA 1/2 및/또는 HRD중국
-
Nordic Society of Gynaecological Oncology - Clinical...모병
LY2963016에 대한 임상 시험
-
Eli Lilly and Company빼는제2형 당뇨병 | 인슐린으로 치료되는 제2형 당뇨병미국
-
Eli Lilly and Company완전한
-
Eli Lilly and Company완전한
-
Eli Lilly and CompanyBoehringer Ingelheim완전한제2형 당뇨병미국, 푸에르토 리코, 멕시코, 대한민국, 독일, 폴란드, 대만, 스페인, 그리스, 프랑스, 체코 공화국, 헝가리
-
Eli Lilly and CompanyBoehringer Ingelheim완전한제1형 당뇨병일본, 미국, 그리스, 벨기에, 폴란드, 독일, 헝가리, 멕시코, 루마니아